Description of the medicine: Zuclopentixol (Zuclopentixol)
(Z) -4- [3- (2-Chlorothioxanthen-9-ylidene) propyl] -1-piperazineethanol.
Synonyms: Clopixol, Clopixol-acuphase, Clopixol, Clopixol-accuphase.
The chemical structure is close to chlorprotixene; differs only in the replacement in the side chain of the dimethylamine radical with an oxyethylpiperazine, characteristic of a number of other antipsychotic drugs (see Etaperazin, Fluphenazine, etc.).
Like chlorprotixen, zuclopentixol has an antipsychotic and sedative effect.
Indications for use are mainly the initial forms of acute and chronic psychoses in the acute phase.
Depending on the dosage form, the drug is used to stop psychoses and for prolonged antipsychotic therapy.
For the relief of psychosis, usually prescribed intramuscularly (in the upper outer quadrant of the gluteal region) clopixol-acufase at 0.05-0.15 g (50-150 mg), if necessary, repeat injections after 1-3 days.
Maintenance therapy can be carried out using tablets in a daily dose of 0.01-0.05 g (50-150 mg) or intramuscular injection of zuclopentixol decanoate (see).
The drug is well tolerated, however, as with the use of antipsychotics, the development of extrapyramidal disorders is possible. In addition, there are: drowsiness, dry mouth, disturbance of accommodation, constipation, urinary retention, orthostatic hypotension and other side effects.
Caution should be exercised in convulsive syndrome, chronic hepatitis, and cardiovascular diseases.
The drug enhances the effect of drugs that depress the central nervous system, reduces - levodopa; metoclopramide and piperazine increase the risk of extrapyramidal disorders.
Release form: tablets on 0,002; 0.01 and 0.025 g (2; 10 and 25 mg) (N.50,100); 5% oil solution of zuclopentixol acetate in ampoules of 1 and 2 ml.
Storage: List B.